215 related articles for article (PubMed ID: 34054818)
1. dmLT Adjuvant Enhances Cytokine Responses to T Cell Stimuli, Whole Cell Vaccine Antigens and Lipopolysaccharide in Both Adults and Infants.
Akhtar M; Nizam NN; Basher SR; Hossain L; Akter S; Bhuiyan TR; Qadri F; Lundgren A
Front Immunol; 2021; 12():654872. PubMed ID: 34054818
[TBL] [Abstract][Full Text] [Related]
2. The adjuvant double mutant Escherichia coli heat labile toxin enhances IL-17A production in human T cells specific for bacterial vaccine antigens.
Leach S; Clements JD; Kaim J; Lundgren A
PLoS One; 2012; 7(12):e51718. PubMed ID: 23284753
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of the oral, inactivated, enterotoxigenic Escherichia coli vaccine ETVAX in Bangladeshi children and infants: a double-blind, randomised, placebo-controlled phase 1/2 trial.
Qadri F; Akhtar M; Bhuiyan TR; Chowdhury MI; Ahmed T; Rafique TA; Khan A; Rahman SIA; Khanam F; Lundgren A; Wiklund G; Kaim J; Löfstrand M; Carlin N; Bourgeois AL; Maier N; Fix A; Wierzba T; Walker RI; Svennerholm AM
Lancet Infect Dis; 2020 Feb; 20(2):208-219. PubMed ID: 31757774
[TBL] [Abstract][Full Text] [Related]
4. Induction of mucosal and systemic immune responses against the common O78 antigen of an oral inactivated ETEC vaccine in Bangladeshi children and infants.
Svennerholm AM; Qadri F; Lundgren A; Kaim J; Rahman Bhuiyan T; Akhtar M; Maier N; Louis Bourgeois A; Walker RI
Vaccine; 2022 Jan; 40(2):380-389. PubMed ID: 34772542
[TBL] [Abstract][Full Text] [Related]
5. Safety, tolerability, and immunogenicity of an oral inactivated ETEC vaccine (ETVAX®) with dmLT adjuvant in healthy adults and children in Zambia: An age descending randomised, placebo-controlled trial.
Sukwa N; Mubanga C; Hatyoka LM; Chilyabanyama ON; Chibuye M; Mundia S; Munyinda M; Kamuti E; Siyambango M; Badiozzaman S; Bosomprah S; Carlin N; Kaim J; Sjöstrand B; Simuyandi M; Chilengi R; Svennerholm AM
Vaccine; 2023 Nov; 41(46):6884-6894. PubMed ID: 37838479
[TBL] [Abstract][Full Text] [Related]
6. Development and preclinical evaluation of safety and immunogenicity of an oral ETEC vaccine containing inactivated E. coli bacteria overexpressing colonization factors CFA/I, CS3, CS5 and CS6 combined with a hybrid LT/CT B subunit antigen, administered alone and together with dmLT adjuvant.
Holmgren J; Bourgeois L; Carlin N; Clements J; Gustafsson B; Lundgren A; Nygren E; Tobias J; Walker R; Svennerholm AM
Vaccine; 2013 May; 31(20):2457-64. PubMed ID: 23541621
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of an improved oral inactivated multivalent enterotoxigenic Escherichia coli (ETEC) vaccine administered alone and together with dmLT adjuvant in a double-blind, randomized, placebo-controlled Phase I study.
Lundgren A; Bourgeois L; Carlin N; Clements J; Gustafsson B; Hartford M; Holmgren J; Petzold M; Walker R; Svennerholm AM
Vaccine; 2014 Dec; 32(52):7077-84. PubMed ID: 25444830
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the safety and immunogenicity of the oral inactivated multivalent enterotoxigenic Escherichia coli vaccine ETVAX in Bangladeshi adults in a double-blind, randomized, placebo-controlled Phase I trial using electrochemiluminescence and ELISA assays for immunogenicity analyses.
Akhtar M; Chowdhury MI; Bhuiyan TR; Kaim J; Ahmed T; Rafique TA; Khan A; Rahman SIA; Khanam F; Begum YA; Sharif MZ; Islam LN; Carlin N; Maier N; Fix A; Wierzba TF; Walker RI; Bourgeois AL; Svennerholm AM; Qadri F; Lundgren A
Vaccine; 2019 Sep; 37(37):5645-5656. PubMed ID: 30473185
[TBL] [Abstract][Full Text] [Related]
9. A Phase 1 dose escalating study of double mutant heat-labile toxin LTR192G/L211A (dmLT) from Enterotoxigenic Escherichia coli (ETEC) by sublingual or oral immunization.
Bernstein DI; Pasetti MF; Brady R; Buskirk AD; Wahid R; Dickey M; Cohen M; Baughman H; El-Khorazaty J; Maier N; Sztein MB; Baqar S; Bourgeois AL
Vaccine; 2019 Jan; 37(4):602-611. PubMed ID: 30563789
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the reactogenicity, adjuvanticity and antigenicity of LT(R192G) and LT(R192G/L211A) by intradermal immunization in mice.
Maciel M; Smith M; Poole ST; Laird RM; Rollenhagen JE; Kaminski RW; Wenzel H; Bourgeois AL; Savarino SJ
PLoS One; 2019; 14(11):e0224073. PubMed ID: 31682624
[TBL] [Abstract][Full Text] [Related]
11. T helper cell responses in adult diarrheal patients following natural infection with enterotoxigenic
Akhtar M; Basher SR; Nizam NN; Hossain L; Bhuiyan TR; Qadri F; Lundgren A
Front Immunol; 2023; 14():1220130. PubMed ID: 37809062
[TBL] [Abstract][Full Text] [Related]
12. LTA1 and dmLT enterotoxin-based proteins activate antigen-presenting cells independent of PKA and despite distinct cell entry mechanisms.
Valli E; Baudier RL; Harriett AJ; Norton EB
PLoS One; 2020; 15(1):e0227047. PubMed ID: 31929548
[TBL] [Abstract][Full Text] [Related]
13. A double mutant heat-labile toxin from Escherichia coli, LT(R192G/L211A), is an effective mucosal adjuvant for vaccination against Helicobacter pylori infection.
Sjökvist Ottsjö L; Flach CF; Clements J; Holmgren J; Raghavan S
Infect Immun; 2013 May; 81(5):1532-40. PubMed ID: 23439305
[TBL] [Abstract][Full Text] [Related]
14. Cholera toxin, and the related nontoxic adjuvants mmCT and dmLT, promote human Th17 responses via cyclic AMP-protein kinase A and inflammasome-dependent IL-1 signaling.
Larena M; Holmgren J; Lebens M; Terrinoni M; Lundgren A
J Immunol; 2015 Apr; 194(8):3829-39. PubMed ID: 25786687
[TBL] [Abstract][Full Text] [Related]
15. Induction of mucosal immune responses against Helicobacter pylori infection after sublingual and intragastric route of immunization.
Sjökvist Ottsjö L; Jeverstam F; Yrlid L; Wenzel AU; Walduck AK; Raghavan S
Immunology; 2017 Feb; 150(2):172-183. PubMed ID: 27676456
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant effect of enterotoxigenic
Seo H; Lu T; Mani S; Bourgeois AL; Walker R; Sack DA; Zhang W
Hum Vaccin Immunother; 2020; 16(2):419-425. PubMed ID: 31361177
[TBL] [Abstract][Full Text] [Related]
17. Immunization with Salmonella Enteritidis secreting mucosal adjuvant labile toxin confers protection against wild type challenge via augmentation of CD3
Lalsiamthara J; Lee JH
Vaccine; 2017 Feb; 35(5):767-773. PubMed ID: 28063704
[TBL] [Abstract][Full Text] [Related]
18. Mucosal Immune Responses Against an Oral Enterotoxigenic Escherichia coli Vaccine Evaluated in Clinical Trials.
Svennerholm AM; Lundgren A; Leach S; Akhtar M; Qadri F
J Infect Dis; 2021 Dec; 224(12 Suppl 2):S821-S828. PubMed ID: 34550392
[TBL] [Abstract][Full Text] [Related]
19. Intradermal or Sublingual Delivery and Heat-Labile Enterotoxin Proteins Shape Immunologic Responses to a CFA/I Fimbria-Derived Subunit Antigen Vaccine against Enterotoxigenic Escherichia coli.
Maciel M; Bauer D; Baudier RL; Bitoun J; Clements JD; Poole ST; Smith MA; Kaminski RW; Savarino SJ; Norton EB
Infect Immun; 2019 Nov; 87(11):. PubMed ID: 31427449
[TBL] [Abstract][Full Text] [Related]
20. Live attenuated enterotoxigenic Escherichia coli (ETEC) vaccine with dmLT adjuvant protects human volunteers against virulent experimental ETEC challenge.
Harro C; Louis Bourgeois A; Sack D; Walker R; DeNearing B; Brubaker J; Maier N; Fix A; Dally L; Chakraborty S; Clements JD; Saunders I; Darsley MJ
Vaccine; 2019 Mar; 37(14):1978-1986. PubMed ID: 30797634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
